• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

EGFR Gene Record

  • Summary
  • Interactions
  • Claims
  • EGFR 1956 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    1956
    EPIDERMAL GROWTH FACTOR RECEPTOR
    EGFR
    ERBB
    ERBB1
    HER1
    NISBD2
    PIG61
    mENA
    131550
    3236
    ENSG00000146648
    OTTHUMG00000023661
    P00533
    EGFR_HUMAN
    19
    Proto-oncogene c-ErbB-1
    Receptor tyrosine-protein kinase erbB-1
    PA7360
    EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER4 (ERBB4)
    EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER3 (ERBB3)
    EGFR (HER1/ERBB1)
    EPIDERMAL GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P00533]
    T59328
    ERRP

    Gene Info:

    CancerCommons Reported Gene Name EGFR
    Target Class Receptors
    Target Subclass EC:2.7.10.1
    Target Subclass Kinase
    Target Main Class Receptors
    Transmembrane Helix Count 1
    Target Subclass EGFR
    Initial Gene Query EGFR
    Counted Citations from 1950-2000 12181
    Human Readable Name DRUGGABLE GENOME
    Interpro Type Domain
    Interpro Acc IPR001245
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Human Readable Name KINASE
    Gene Biotype PROTEIN_CODING
    (29 More Sources)

    Gene Categories: Category Details

    CELL SURFACE
    KINASE
    TYROSINE KINASE
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE

    Publications:

    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
    Ward RA et al., 2013, Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)., J Med Chem
    Yasuda et al., 2012, EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications., Lancet Oncol.
    Engelman et al., 2007, PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib., Cancer Res.
    Jänne et al., 2014, Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial., Lancet Oncol.
    Zahonero et al., 2015, Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma., Mol. Cancer Ther.
    Ma et al., 2016, InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma., Clin. Cancer Res.
    Kobayashi et al., 2015, EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs., Clin. Cancer Res.
    Kobayashi et al., 2017, Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer., Mol. Cancer Ther.
    Kosaka et al., 2017, Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors., Cancer Res.
    Gerber et al., 2014, Management and future directions in non-small cell lung cancer with known activating mutations., Am Soc Clin Oncol Educ Book
    Wu YL et al., 2017, Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial., Lancet Oncol
    Sequist et al., 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors., Sci Transl Med
    Ramalingam et al., 2016, Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials., Ann. Oncol.
    Brzezniak C et al., 2013, Dacomitinib, a new therapy for the treatment of non-small cell lung cancer., Expert Opin Pharmacother
    Fry et al., 1998, Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor., Proc. Natl. Acad. Sci. U.S.A.
    Montagut et al., 2012, Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer., Nat. Med.
    Lynch et al., 2002, Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment., Semin. Oncol.
    Heymach et al., 2006, Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer., Clin. Cancer Res.
    Yang et al., 2001, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy., Crit. Rev. Oncol. Hematol.
    Keating, 2010, Panitumumab: a review of its use in metastatic colorectal cancer., Drugs
    Wu et al., 2008, Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer., Clin Ther
    Jean et al., 2008, Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer., Pharmacotherapy
    Foon et al., 2004, Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody., Int. J. Radiat. Oncol. Biol. Phys.
    Saadeh et al., 2007, Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer., Ann Pharmacother
    Keating, 2010, Spotlight on panitumumab in metastatic colorectal cancer., BioDrugs
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Segaert et al., 2005, Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors., Ann. Oncol.
    Cohen, 2003, Epidermal growth factor receptor as a therapeutic target in colorectal cancer., Clin Colorectal Cancer
    Sebio A et al., 2014, Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan., Pharmacogenomics J
    Rossi A et al., 2013, Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?, Cancer Treat Rev
    Mayo C et al., 2012, Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications., Pharmacogenomics
    Van Cutsem et al., 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer., N. Engl. J. Med.
    Vermorken JB et al., 2008, Platinum-based chemotherapy plus cetuximab in head and neck cancer., N Engl J Med
    Funke S et al., 2008, Pharmacogenetics in colorectal cancer: a systematic review., Pharmacogenomics
    Giusti RM et al., 2008, U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens., Clin Cancer Res
    Jonker et al., 2007, Cetuximab for the treatment of colorectal cancer., N. Engl. J. Med.
    Bonner JA et al., 2006, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck., N Engl J Med
    Normanno N et al., 2006, Epidermal growth factor receptor (EGFR) signaling in cancer., Gene
    Thatcher N et al., 2005, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)., Lancet
    Herbst RS et al., 2004, Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2., J Clin Oncol
    Giaccone G et al., 2004, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1., J Clin Oncol
    Jorissen RN et al., 2003, Epidermal growth factor receptor: mechanisms of activation and signalling., Exp Cell Res
    Oddo et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res.
    Sartore-Bianchi et al., 2007, Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab., J. Clin. Oncol.
    Arena et al., 2016, MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations., Sci Transl Med
    Sánchez-Martín et al., 2016, The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer., Clin. Cancer Res.
    Shen et al., 2014, EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis., Chin. J. Cancer Res.
    Uchibori et al., 2017, Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer., Nat Commun
    Strickler JH et al., 2018, Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer., Cancer Discov
    Schuster et al., 2015, A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study., Neuro-oncology
    Rateb ME et al., 2009, Bioactive diterpene derivatives from the marine sponge Spongionella sp., J Nat Prod
    Sheng M et al., 2016, Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis., Eur J Clin Pharmacol
    Cho SH et al., 2012, Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation., Cancer Chemother Pharmacol
    Oizumi S et al., 2012, Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial., Oncologist
    Han et al., 2012, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung., J. Clin. Oncol.
    Liu G et al., 2012, Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer., J Thorac Oncol
    Su et al., 2012, Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer., J. Clin. Oncol.
    Nakamura T et al., 2011, A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA., J Thorac Oncol
    Goto K et al., 2012, Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer., J Thorac Oncol
    Rosell et al., 2011, Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations., Clin. Cancer Res.
    Maemondo et al., 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR., N. Engl. J. Med.
    Douillard et al., 2010, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial., J. Clin. Oncol.
    Mitsudomi et al., 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial., Lancet Oncol.
    Mok et al., 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma., N. Engl. J. Med.
    Onitsuka T et al., 2010, Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status., Lung Cancer
    Tiseo M et al., 2010, Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers., Lung Cancer
    Chen HJ et al., 2009, Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer., Pathol Oncol Res
    Ma F et al., 2009, Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib., Lung Cancer
    Sugio K et al., 2009, Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations., Lung Cancer
    Rakhit A et al., 2008, The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition., Eur J Clin Pharmacol
    Nie Q et al., 2007, The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib., Eur J Pharmacol
    Wu YL et al., 2007, Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China., J Thorac Oncol
    Han SW et al., 2007, Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer., Pharmacogenet Genomics
    Liu G et al., 2008, Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib., Pharmacogenomics J
    Hirsch FR et al., 2007, Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib., Ann Oncol
    Sequist et al., 2007, Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing., Oncologist
    Ichihara S et al., 2007, The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer., Int J Cancer
    Balak et al., 2006, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors., Clin. Cancer Res.
    Kosaka T et al., 2006, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib., Clin Cancer Res
    Han SW et al., 2006, Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients., Lung Cancer
    Inukai et al., 2006, Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer., Cancer Res.
    Endo K et al., 2006, Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy., Oncol Rep
    Bell et al., 2005, Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR., Nat. Genet.
    Bell DW et al., 2005, Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials., J Clin Oncol
    Tomizawa Y et al., 2005, Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer., Clin Cancer Res
    Taron et al., 2005, Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas., Clin. Cancer Res.
    Chou et al., 2005, Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer., Clin. Cancer Res.
    Lynch et al., 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib., N. Engl. J. Med.
    Ban HS et al., 2010, Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines., Bioorg Med Chem
    Zhang D et al., 2013, Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors., Bioorg Med Chem
    Carmi C et al., 2010, Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion., J Med Chem
    Yu H et al., 2014, A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer., Cancer Biol Ther
    Wu et al., 2011, Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer., Clin. Cancer Res.
    Pao et al., 2004, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib., Proc. Natl. Acad. Sci. U.S.A.
    Ludovini V et al., 2011, Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer., J Thorac Oncol
    Wang et al., 2012, Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR., J. Exp. Clin. Cancer Res.
    Fukuoka et al., 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]., J. Clin. Oncol.
    Mellinghoff et al., 2005, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors., N. Engl. J. Med.
    Dziadziuszko et al., 2006, Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer., Clin. Cancer Res.
    Zhang X et al., 2017, EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis., J Investig Med
    Dahabreh et al., 2011, EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer., Ann. Oncol.
    Otsuka et al., 2015, Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212)., Anticancer Res.
    Jackman et al., 2006, Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib., Clin. Cancer Res.
    Ji et al., 2006, The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies., Cancer Cell
    Belchis et al., 2016, Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma., Oncotarget
    Yu et al., 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers., Clin. Cancer Res.
    Yun et al., 2008, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP., Proc. Natl. Acad. Sci. U.S.A.
    Kobayashi et al., 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib., N. Engl. J. Med.
    Kancha et al., 2009, Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy., Clin. Cancer Res.
    Yang et al., 2008, Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy., J. Clin. Oncol.
    Paez et al., 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy., Science
    Fukihara et al., 2014, Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer., Oncology
    Lim et al., 2014, Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21., J Thorac Oncol
    Takeuchi et al., 2012, Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer., Am. J. Pathol.
    Engelman et al., 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling., Science
    Liang et al., 2014, Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations., PLoS ONE
    Niu et al., 2014, Novel agents and strategies for overcoming EGFR TKIs resistance., Exp Hematol Oncol
    Eberlein et al., 2015, Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models., Cancer Res.
    Pao et al., 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain., PLoS Med.
    Ma et al., 2011, T790M and acquired resistance of EGFR TKI: a literature review of clinical reports., J Thorac Dis
    Koole et al., 2016, FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma., Clin. Cancer Res.
    Shien et al., 2013, Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells., Cancer Res.
    Rho et al., 2014, MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation., Cancer Res.
    Yamaoka et al., 2016, Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation., Mol. Cancer Ther.
    Della Corte et al., 2015, SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer., Clin. Cancer Res.
    Chen et al., 2016, Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations., Onco Targets Ther
    Peters et al., 2012, Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann. Oncol.
    Niederst et al., 2015, The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies., Clin. Cancer Res.
    Lin et al., 2017, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer., Clin Lung Cancer
    Foster et al., 2010, Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma., World J Surg Oncol
    Ercan et al., 2015, EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors., Clin. Cancer Res.
    Costa et al., 2008, Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib., Clin. Cancer Res.
    Verma et al., 2017, Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis., Cancer Res.
    Yasuda et al., 2013, Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer., Sci Transl Med
    Yeh et al., 2013, DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy., Clin. Cancer Res.
    Szerlip et al., 2012, Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response., Proc. Natl. Acad. Sci. U.S.A.
    Okada-Iwasaki et al., 2016, The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase., Mol. Cancer Ther.
    Goss et al., 2013, Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study., J. Clin. Oncol.
    Kim et al., 2015, Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors., Mol. Cancer Res.
    Lou et al., 2014, Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells., PLoS ONE
    Yang et al., 2011, Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene., J. Clin. Oncol.
    Udager et al., 2015, High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma., Cancer Res.
    Yun et al., 2007, Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity., Cancer Cell
    Moasser et al., 2001, The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells., Cancer Res.
    Albanell et al., 2001, Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments., Cancer Res.
    Ciardiello et al., 2000, Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor., Clin. Cancer Res.
    Arteaga et al., 2001, Tyrosine kinase inhibitors-ZD1839 (Iressa)., Curr Opin Oncol
    Nicholson et al., 2001, Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer., Endocr. Relat. Cancer
    Murray et al., 2010, Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study., J Oncol
    Lewis et al., 2012, A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck., Clin. Cancer Res.
    Geoerger B et al., 2008, EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts., Int J Cancer
    Yang JC et al., 2020, A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis., J Thorac Oncol
    Chang et al., Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study., Biomed J
    Xu JM et al., 2009, EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib., J Cancer Res Clin Oncol
    Liao BC et al., 2015, Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer., Curr Opin Oncol
    Rajasekaran et al., 2010, In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs., Appl. Biochem. Biotechnol.
    Shi et al., 2013, Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial., Lancet Oncol.
    Rosell et al., 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol.
    Sequist et al., 2013, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations., J. Clin. Oncol.
    Fukuoka et al., 2011, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)., J. Clin. Oncol.
    Kosaka et al., 2009, Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma., J Thorac Oncol
    Marks et al., 2008, Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma., J Thorac Oncol
    Yang et al., 2012, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial., Lancet Oncol.
    Rosell et al., 2009, Screening for epidermal growth factor receptor mutations in lung cancer., N. Engl. J. Med.
    Zhou et al., 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study., Lancet Oncol.
    Miller et al., 2012, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial., Lancet Oncol.
    Mulloy et al., 2007, Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib., Cancer Res.
    Walter et al., 2013, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC., Cancer Discov
    Zhou et al., 2009, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M., Nature
    Jänne et al., 2015, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer., N. Engl. J. Med.
    Hirano et al., 2015, In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer., Oncotarget
    Ding et al., 2014, The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis., Onco Targets Ther
    Ai et al., 2014, A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity., Amino Acids
    Katakami et al., 2013, LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both., J. Clin. Oncol.
    Girard et al., 2010, Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report., Clin. Cancer Res.
    Cross et al., 2014, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer., Cancer Discov
    Oxnard et al., 2012, Screening for germline EGFR T790M mutations through lung cancer genotyping., J Thorac Oncol
    Sequist et al., 2016, Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib., JAMA Oncol
    Li et al., 2014, Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients., Onco Targets Ther
    Denis et al., 2015, EGFR T790M resistance mutation in non small-cell lung carcinoma., Clin. Chim. Acta
    Sequist et al., 2015, Rociletinib in EGFR-mutated non-small-cell lung cancer., N. Engl. J. Med.
    Watanabe et al., 2011, Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis., BMC Cancer
    Li et al., 2014, Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC., Lung Cancer
    Fu et al., 2008, EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy., Oncogene
    Guo et al., 2006, Gefitinib-sensitizing mutations in esophageal carcinoma., N. Engl. J. Med.
    Eberhard et al., 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib., J. Clin. Oncol.
    Sequist et al., 2008, First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations., J. Clin. Oncol.
    Kobayashi et al., 2013, Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors., J Thorac Oncol
    Schick et al., 1990, Effects of marine oil-enriched diets on guinea pig megakaryocyte and platelet lipids: effects on thromboxane synthesis and platelet function., Biochim. Biophys. Acta
    Berge et al., 2013, Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR., J Thorac Oncol
    Jiang et al., 2005, Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression., Cancer Res.
    Cho et al., 2014, Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab., Mol. Cancer
    Greulich et al., 2005, Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants., PLoS Med.
    Gilmer et al., 2008, Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib., Cancer Res.
    MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
    Ramalingam et al., 2012, Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer., J. Clin. Oncol.
    Sequist et al., 2010, Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer., J. Clin. Oncol.
    Huang et al., 2013, MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib., Mol Oncol
    Mitsudomi et al., 2010, Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer., FEBS J.
    Tam et al., 2009, Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations., Mol. Cancer Ther.
    Han et al., 2005, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib., J. Clin. Oncol.
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
    Rosell et al., 2005, Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer., Lung Cancer
    Yang et al., 2015, Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6., Lancet Oncol.
    Park et al., 2016, Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial., Lancet Oncol.
    Yang et al., 2015, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials., Lancet Oncol.
    Sun et al., 2013, Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors., Lung Cancer
    Dungo et al., 2013, Afatinib: first global approval., Drugs
    Wu et al., 2014, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial., Lancet Oncol.
    Ji X et al., 2014, Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors., Bioorg Med Chem
    Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov
    Konduri et al., 2016, EGFR Fusions as Novel Therapeutic Targets in Lung Cancer., Cancer Discov
    Passaro et al., 2013, Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials., J Thorac Dis
    Pirazzoli et al., 2014, Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1., Cell Rep
    Smith et al., 2015, The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer., Target Oncol
    Pirazzoli et al., 2016, Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma., Clin. Cancer Res.
    Krall et al., 2017, KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer., Elife
    Wu et al., 2016, The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients., Oncotarget
    He et al., 2012, EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma., Clin. Cancer Res.
    Khelwatty et al., 2011, Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members., Int. J. Oncol.
    Tsai et al., 2015, Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells., Mol. Cancer Ther.
    Nakamura et al., 2016, Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC., Mol. Cancer Ther.
    Young et al., 2015, Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo., Target Oncol
    Choudhury et al., 2016, Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations., J. Clin. Oncol.
    Gallant et al., 2015, EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib., Cancer Discov
    Heigener et al., 2015, Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors., Oncologist
    D'Arcangelo et al., 2014, Clinical and comparative utility of afatinib in non-small cell lung cancer., Biologics
    Jensen KV et al., 2020, EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo., Neurooncol Adv
    Starrett JH et al., 2020, Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance <i>EGFR</i> Mutations., Cancer Res
    Kuenen et al., 2010, A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies., Clin. Cancer Res.
    Mu et al., 2014, AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models., J. Exp. Clin. Cancer Res.
    Hickinson et al., 2010, AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer., Clin. Cancer Res.
    Xia et al., 2002, Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways., Oncogene
    Johnston et al., 2006, Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer., Drugs Today
    Zhou et al., 2004, Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance., Int. J. Radiat. Oncol. Biol. Phys.
    Tevaarwerk et al., 2009, Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer., Clin Ther
    Vazquez-Martin et al., 2011, Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth., J. Cell. Physiol.
    Wood et al., 2004, A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells., Cancer Res.
    Grana et al., 2003, Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance., Cancer Res.
    Burris, 2004, Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib., Oncologist
    Xia et al., 2004, Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016., Oncogene
    Langer, 2004, Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC., Int. J. Radiat. Oncol. Biol. Phys.
    Medina et al., 2008, Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases., Clin Ther
    Li et al., 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models., Oncogene
    Lyu A et al., 2014, Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates., Eur J Med Chem
    Sridhar J et al., 2014, Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer., Bioorg Med Chem Lett
    Frattini et al., 2013, The integrated landscape of driver genomic alterations in glioblastoma., Nat. Genet.
    Ross et al., 2010, Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer., Clin. Cancer Res.
    Secrier et al., 2016, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance., Nat. Genet.
    Leslie et al., 2012, Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer., Gynecol. Oncol.
    Mallon et al., 2011, Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor., Clin. Cancer Res.
    Thress et al., 2015, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M., Nat. Med.
    Nukaga et al., 2017, Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors., Cancer Res.
    Mok et al., 2017, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer., N. Engl. J. Med.
    Greig, 2016, Osimertinib: First Global Approval., Drugs
    Ortiz-Cuaran et al., 2016, Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors., Clin. Cancer Res.
    Ou et al., 2016, High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression., Lung Cancer
    Moores et al., 2016, A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors., Cancer Res.
    Ballard et al., 2016, Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity., Clin. Cancer Res.
    Peters et al., 2017, Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies., J Thorac Oncol
    Ichihara et al., 2017, SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer., Cancer Res.
    Yosaatmadja et al., 2015, Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed., J. Struct. Biol.
    Cho JH et al., 2020, Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)., J Clin Oncol
    Castellano GM et al., 2019, A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib., J Thorac Oncol
    Nakayama et al., 2013, Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model., J Cancer
    Gavai et al., 2009, Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases., J. Med. Chem.
    Soria et al., 2012, Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors., Ann. Oncol.
    Lee et al., 2015, A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients., Clin. Cancer Res.
    Satoh et al., 2015, Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer., Gastric Cancer
    Gettinger et al., 2016, Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial., Lancet Oncol.
    Zhang et al., 2016, The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models., Clin. Cancer Res.
    Gerdes et al., 2013, GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab., Clin. Cancer Res.
    Gainor et al., 2016, EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis., Clin. Cancer Res.
    Hastings K et al., 2019, EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer., Ann Oncol
    Suzuki et al., 2007, Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor., Cancer Sci.
    Lara et al., 2015, Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib., Clin. Cancer Res.
    Haratani et al., 2017, Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment., Ann. Oncol.
    Zhang et al., 2013, Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer., Carcinogenesis
    Kang et al., 2016, ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models., Lung Cancer
    Yang et al., 2016, AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases., Sci Transl Med
    Khozin et al., 2014, U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations., Oncologist
    Rosell et al., 2017, Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial., Lancet Respir Med
    Kelly et al., 2015, Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial., J. Clin. Oncol.
    Park et al., 2016, First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study., JAMA Oncol
    Johnson et al., 2015, Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors., J. Clin. Oncol.
    Kotschy et al., 2016, The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models., Nature
    Wen et al., 2014, Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02., Neuro-oncology
    Bean et al., 2008, Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma., Clin. Cancer Res.
    Keller et al., 2016, A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma., Mol. Cancer Res.
    Tang et al., 2009, Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity., Oncogene
    Neal et al., 2016, Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial., Lancet Oncol.
    Lee et al., 2006, Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain., PLoS Med.
    Delbaldo et al., 2003, [Epidermal growth factor inhibitors]., Rev Med Interne
    Akita et al., 2003, Preclinical studies with Erlotinib (Tarceva)., Semin. Oncol.
    Kim et al., 2002, Erlotinib OSI/Roche/Genentech., Curr Opin Investig Drugs
    Bulgaru et al., 2003, Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase., Expert Rev Anticancer Ther
    Laird et al., 2003, Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents., Expert Opin Investig Drugs
    Zhu YC et al., 2018, EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report., Lung Cancer
    Klughammer et al., 2016, Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations., J Thorac Oncol
    Hellmann et al., 2014, Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib., J Thorac Oncol
    Brugger et al., 2011, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer., J. Clin. Oncol.
    de Gunst et al., 2007, Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain., Mol. Cancer
    Cadranel J et al., 2012, Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2)., J Thorac Oncol
    Puyo S et al., 2008, Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro., Mol Diagn Ther
    Miller VA et al., 2008, Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib., J Clin Oncol
    Rudin CM et al., 2008, Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity., J Clin Oncol
    Perez-Soler R, 2004, The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer., Clin Cancer Res
    De Pas T et al., 2011, Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations., J Thorac Oncol
    Pérez-Soler R et al., 2004 Aug 15, Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer., J Clin Oncol
    Tsao MS et al., 2005, Erlotinib in lung cancer - molecular and clinical predictors of outcome., N Engl J Med
    Cecchini M et al., 2017, <i>EGFR</i> Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by <i>T790M</i>-Mediated Resistance., J Natl Compr Canc Netw
    Martinelli et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int. J. Cancer
    Wada K et al., 2015, Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects., Bioorg Med Chem
    Phillips et al., 2016, ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope., Mol. Cancer Ther.
    Newman DJ et al., 2014, Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development., Mar Drugs
    Tang et al., 2008, Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer., Br. J. Cancer
    Van Schaeybroeck et al., 2006, Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells., Mol. Cancer Ther.
    Cleary et al., 2015, A phase 1 study of ABT-806 in subjects with advanced solid tumors., Invest New Drugs
    Blair JA et al., 2007, Structure-guided development of affinity probes for tyrosine kinases using chemical genetics., Nat Chem Biol
    Vacondio F et al., 2013, Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors., Bioorg Med Chem Lett
    Smaill JB et al., 1999, Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor., J Med Chem
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Lai et al., 2010, CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity., Cancer Res.
    Tang et al., 2015, BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers., Mol. Cancer Ther.
    Ganesan et al., 2016, Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy., J. Clin. Oncol.
    Personeni et al., 2008, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study., Clin. Cancer Res.
    Arena et al., 2015, Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer., Clin. Cancer Res.
    Braig et al., 2015, Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer., Oncotarget
    Hosokawa et al., 1999, Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells., J. Antibiot.
    Burke et al., 2001, Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking., Mol. Biol. Cell
    Suwa et al., Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells., Anticancer Res.
    Viloria-Petit et al., 2001, Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis., Cancer Res.
    Wakita et al., 1999, Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes., J. Biol. Chem.
    Bahassi et al., 2013, A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer., Eur. J. Cancer
    Cho et al., 2013, Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization., Cancer Res.
    Wang et al., 2016, Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report., Medicine (Baltimore)
    Jia et al., 2016, Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors., Nature
    Zhang et al., 2013, A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy., Sci Rep
    Luber B et al., 2011, Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)., BMC Cancer
    Erlichman et al., 2006, Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors., J. Clin. Oncol.
    Yoshimura et al., 2006, EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib., Lung Cancer
    Dietlein et al., 2015, A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer., Cell
    Hong JY et al., 2011, Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa., J Nat Prod
    Zhang et al., 1999, Chronic ethanol consumption disrupts complexation between EGF receptor and phospholipase C-gamma1: relevance to impaired hepatocyte proliferation., Biochem. Biophys. Res. Commun.
    Perera et al., 2017, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor., Mol. Cancer Ther.
    Bleeker WK et al., 2004, Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy., J Immunol
    Qiu HB et al., 2018, Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1., Pharmacogenomics J
    Gannon et al., 2016, Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy., Mol. Cancer Res.
    Tricker et al., 2015, Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer., Cancer Discov
    Pietanza et al., 2012, Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer., J Thorac Oncol
    Kaspersen et al., 2011, Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines., Eur J Med Chem
    Tanaka et al., 2014, Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2., Cancer Sci.
    Spicer et al., 2015, Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours., Eur. J. Cancer
    Soria et al., 2013, Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours., Eur. J. Cancer
    Mills et al., 1990, Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells., J. Clin. Invest.
    Hu et al., 2014, A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)., Lung Cancer
    Shao et al., 2014, Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy., Chin. Med. J.
    Gu et al., 2013, Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer., Chin. J. Cancer Res.
    Chilin A et al., 2010, Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold., J Med Chem
    Paz-Ares et al., 2015, Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens., J Thorac Oncol
    Blumenschein et al., 2013, Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial., Clin. Cancer Res.
    Diez-Cecilia E et al., 2015, Probing a 3,4'-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway., Bioorg Med Chem Lett
    Takahashi H et al., 2013, Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data., J Biosci Bioeng
    Li X et al., 2014, Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity., J Med Chem
    Tan CS et al., 2016, Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer., Lung Cancer
    Ratner et al., 2012, A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer., Oncogene
    Hudkins RL et al., 2012, Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent., J Med Chem
    Zhou X et al., 2006, Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb., Bioorg Med Chem Lett
    Xu et al., 2016, AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients., Mol. Cancer Ther.
    Sakaguchi et al., 2006, The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor., Anesth. Analg.
    Challa et al., 2016, IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR., Cancer Res.
    Markham A, 2017, Brigatinib: First Global Approval., Drugs
    Iragavarapu C et al., 2015, Novel ALK inhibitors in clinical use and development., J Hematol Oncol
    Ceccon M et al., 2013, Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors., Mol Cancer Res
    Qu et al., 2014, Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models., J. Exp. Clin. Cancer Res.
    Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
    Chabon et al., 2016, Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients., Nat Commun
    Sasaki et al., 2011, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors., Cancer Res.
    Etienne-Grimaldi MC et al., 2012, Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan., Br J Clin Pharmacol
    Asnavandi M et al., 2017, EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C., Genes Immun
    Selig R et al., 2012, A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors., J Med Chem
    Petch D et al., 2012, Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis., Bioorg Med Chem
    Schleissner C et al., 2011, Antitumor actinopyranones produced by Streptomyces albus POR-04-15-053 isolated from a marine sediment., J Nat Prod
    Wu S et al., 2020, <i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma., Clin Cancer Res
  • AFATINIB   EGFR

    Interaction Score: 4.75

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Clinical Status NCCN/ CAP guidelines
    Clinical Status early trials
    Variant Effect gain-of-function

    PMIDs:
    25611025 11255078 23022519 22594511 19339720 18784101 18681783 18316547 18003960 16467544 16377102 16257339 14990633 14990632 12648464 19455431 23948351 20022809 22285168 19692680 23816960 21670455 19096302 18303429 22452895 19692684 20573926 21783417 22452896 17332364 24065731 16258541 15737014 20033049 25923549 26515464 24623981 18227510 16912157 15728811 21531810 24658966 22215752 23816963 20068085 24893891 21430269 22588155 26720284 24729716 25668228 25923550 21194487 24636847 21233402 17653080 19147750 16707764 16043828 18458038 23242437 2302402 23945392 16204070 24894453 16187797 18199554 25157968 22753918 20479403 15118125 15329413 23102728 19922469 15118073 19671738 16115929 15710947 26619011 16011858 26051236 27083334 25589191 24035188 27304188 23982599 24439929 23930994 24565969 27694386 27102076 23991291 25870145 24813888 25077897 26341921 28145866 26862733 22190593 21617858 25589492 25964297 27207775 25559287 27044931 26286086 26206867 23344264 17349580 27913578 25948633 24353160 28363995 26354527 24790411 32226941 32193290


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial JAX-CKB DoCM COSMIC CIViC MyCancerGenomeClinicalTrial PharmGKB FDA OncoKB

  • ROCILETINIB   EGFR

    Interaction Score: 2.58

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

    PMIDs:
    28202511 24065731 25923550


    Sources:
    MyCancerGenome ChemblInteractions CIViC TTD

  • OSIMERTINIB   EGFR

    Interaction Score: 2.43

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy AZD9291 + JNJ-61186372
    Approval Status Preclinical - Cell line xenograft
    Approval Status FDA approved

    PMIDs:
    25939061 28202511 27959700 26729184 26720284 25923549 24893891 27694386 27102076 24410791 27252416 27393507 27216193 27435396 25870145 26286086 28343545 26206867 25948633 28416483 26522274 32193290 31825714 31254668


    Sources:
    MyCancerGenome JAX-CKB ChemblInteractions COSMIC CIViC PharmGKB TTD FDA OncoKB

  • DACOMITINIB   EGFR

    Interaction Score: 2.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name PF-299804
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    23930994 21764376 18089823 25456362 25939761 26561558 26206867 27913578 28363995 24857124 28958502 21430269 26768165 23294134 9751783


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial PharmGKB TTD FDA OncoKB

  • ICOTINIB   EGFR

    Interaction Score: 1.84

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response

    PMIDs:
    24533047 27468240 2394835 25261231 24438614 23372346


    Sources:
    TALC MyCancerGenome JAX-CKB MyCancerGenomeClinicalTrial

  • ZALUTUMUMAB   EGFR

    Interaction Score: 1.84

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name HuMax-EGFr
    Notes

    PMIDs:
    15383606


    Sources:
    TALC TdgClinicalTrial ChemblInteractions TTD

  • DEPATUXIZUMAB   EGFR

    Interaction Score: 1.47

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Evidence Type Actionable
    Response Type predicted – sensitive
    Indication/Tumor Type Advanced Solid Tumor

    PMIDs:
    25895099


    Sources:
    MyCancerGenome JAX-CKB TTD

  • RINDOPEPIMUT   EGFR

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name rindopepimut, CDX-110
    Novel drug target Established target

    PMIDs:
    25586468


    Sources:
    TdgClinicalTrial CIViC TTD

  • ERLOTINIB   EGFR

    Interaction Score: 1.34

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy MGCD265 + Erlotinib
    Approval Status Phase III
    combination therapy AUY922 + Erlotinib

    PMIDs:
    27694386 24410791 26341921 23917401 24868098 27468240 28408243 26324372 26720423 25870087 27913578 27102076 27760111 24470557 19010870 27793840 27216155 27207775 22190593 20942962 26286086 28089594 19015641 27825638 17177598 18981003 25077897 24353160 25573954 23344264 19147750 26106072 25931286 28343545 26206867 17349580 19455431 23948351 20022809 22285168 19692680 23816960 21670455 19096302 18303429 22452895 19692684 20573926 21783417 22452896 17332364 24065731 16258541 15737014 20033049 25923549 26515464 24623981 18227510 16912157 15728811 21531810 24658966 22215752 23816963 20068085 24893891 21430269 22588155 26720284 24729716 25668228 25923550 21194487 24636847 21233402 17653080 16707764 16043828 18458038 23242437 2302402 23945392 16204070 24894453 16187797 18199554 25157968 22753918 20479403 15118125 15329413 23102728 19922469 15118073 19671738 16115929 15710947 26619011 16011858 12814826 12840797 12498017 12820772 11752352 12517254 29290255 26773740 17085664 25521405 21969500 21258250 22901364 16282176 27664271 20826716 26124334 26768165 16818686 27304188 23470965 17877814 24457318 24736073 19969465 24565969 26490356 22982650 22760226 21921847 19589612 19381876 18992959 18652519 18349398 18309947 17285735 17020982 15217965 11255078 23022519 22594511 19339720 18784101 18681783 18316547 18003960 16467544 16377102 16257339 14990633 14990632 12648464 21841502 15310767 16014883 32193290 28874593 25179728


    Sources:
    TALC DTC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TEND DoCM COSMIC CIViC CancerCommons PharmGKB TTD FDA OncoKB

  • OLMUTINIB   EGFR

    Interaction Score: 1.1

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    26898616


    Sources:
    JAX-CKB ChemblInteractions

  • PKI-166   EGFR

    Interaction Score: 1.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    22018877


    Sources:
    DTC ChemblInteractions

  • NECITUMUMAB   EGFR

    Interaction Score: 1.1

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name necitumumab , IMC-11F8
    Novel drug target Established target
    Notes

    PMIDs:
    20197484


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

  • CETUXIMAB   EGFR

    Interaction Score: 0.92

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    24934779 22270724 26888827 18003960 18794099 24653627 24894453 25623215 26059438 10480573 11408594 10628369 11431346 11752352 10601294 19455431 23948351 20022809 22285168 19692680 23816960 21670455 19096302 18303429 22452895 19692684 20573926 21783417 22452896 17332364 24065731 16258541 15737014 20033049 25923549 26515464 24623981 18227510 16912157 15728811 21531810 24658966 22215752 23816963 20068085 24893891 21430269 22588155 26720284 24729716 25668228 25923550 21194487 24636847 21233402 17653080 19147750 16707764 18089823 16043828 18458038 23242437 2302402 23945392 16204070 16187797 18199554 25157968 22753918 20479403 15118125 15329413 23102728 19922469 15118073 19671738 16115929 15710947 26619011 16011858 23578570 27102076 24063894 24813888 26341921 27149458 25948633 27251290 27207775 24141978 27312529 27216155 26843189 28287083 22152101 29196463


    Sources:
    TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TEND DoCM CIViC CancerCommons TTD FDA

  • S-222611   EGFR

    Interaction Score: 0.92

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes
    Indication/Tumor Type Advanced Solid Tumor

    PMIDs:
    24837299 25434923


    Sources:
    JAX-CKB ChemblInteractions TTD

  • CHEMBL285063   EGFR

    Interaction Score: 0.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17334377 23988354 10346932 10592235


    Sources:
    DTC

  • NIMOTUZUMAB   EGFR

    Interaction Score: 0.92

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Notes
    Novel drug target Established target
    Trial Name Nimotuzumab

    PMIDs:
    25185971


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB

  • NERATINIB   EGFR

    Interaction Score: 0.87

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type head and neck squamous cell carcinoma
    Approval Status Phase II
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    11255078 23022519 22594511 19339720 18784101 18681783 18316547 18003960 16467544 16377102 16257339 14990633 14990632 12648464 21325073 17085664 25931286 26206867 20479403 25948633


    Sources:
    TALC TdgClinicalTrial JAX-CKB ChemblInteractions PharmGKB TTD

  • PELITINIB   EGFR

    Interaction Score: 0.86

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Indication/Tumor Type Advanced Solid Tumor

    PMIDs:
    16710023 16364494


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions TTD

  • AC-480   EGFR

    Interaction Score: 0.83

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name AC480
    Novel drug target Established target
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

    PMIDs:
    19821562 21576284


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TTD

  • PANITUMUMAB   EGFR

    Interaction Score: 0.81

    Interaction Types & Directionality:
    suppressor (inhibitory)
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes
    Novel drug target Established target

    PMIDs:
    22270724 11894013 16857825 11255078 20481659 18343240 18503402 14967460 17355997 20623992 11752352 16012181 12620146 23959273 23022519 22594511 19339720 18784101 18681783 18316547 18003960 16467544 16377102 16257339 14990633 14990632 12648464 27312529 17664472 26843189 26888827 24653627 28287083 29196463


    Sources:
    TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TEND DoCM CIViC PharmGKB TTD FDA

  • GEFITINIB   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Iressa
    Novel drug target Established target
    Indication/Tumor Type colorectal cancer

    PMIDs:
    26490356 22760226 22581822 22370314 22237259 22215752 21921847 21900837 21233402 20573926 20038723 20022809 19692680 19589612 19473722 19381876 19201048 18992959 18000659 17597605 17473659 17429313 17375033 17317677 17285735 17192902 17085664 17020982 16956694 16912157 16865253 16258541 16204011 16203769 16115929 15897572 15118073 11255078 23022519 22594511 19339720 18784101 18681783 18316547 18003960 16467544 16377102 16257339 14990633 14990632 12648464 19969465 23993328 20151670 24755888 21531810 15329413 21258250 22901364 12748244 16282176 16707605 27664271 20826716 26124334 16818686 16730237 27304188 23470965 18227510 15728811 19147750 18509184 15118125 24457318 24736073 22789825 17463250 24533047 24410791 25870145 15737014 22263058 26936917 23542356 24165158 27612490 26124204 27468240 22997455 27312529 25964297 28089594 20942962 25948633 18981003 27793840 24353160 23344264 22323597 27196752 23980091 25573954 24874286 21422421 25931286 26561558 26206867 17349580 11585753 11522647 10815932 11673690 11566608 11752352 21274259 22261807 18386816 31605797 25179728 19020901


    Sources:
    TALC DTC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TEND DoCM COSMIC CIViC MyCancerGenomeClinicalTrial PharmGKB TTD FDA OncoKB

  • CHEMBL1078000   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19601607


    Sources:
    DTC

  • EPITINIB   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    None found


    Sources:
    JAX-CKB ChemblInteractions

  • GRACILIN A   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19601607


    Sources:
    DTC

  • BRIGATINIB   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    28287083 28597393 25888090 23239810


    Sources:
    ChemblInteractions CIViC

  • ABIVERTINIB MALEATE   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    27573423


    Sources:
    JAX-CKB

  • CHEMBL472212   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gefitinib + PF-431396
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture

    PMIDs:
    27793840


    Sources:
    JAX-CKB

  • MATUZUMAB   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • DEPATUXIZUMAB MAFODOTIN   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung squamous cell carcinoma
    Indication/Tumor Type glioblastoma multiforme
    Response Type predicted – sensitive

    PMIDs:
    26846818 24424355


    Sources:
    JAX-CKB TTD

  • AZD-3759   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Approval Status Clinical Study
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    27928026


    Sources:
    JAX-CKB

  • CHEMBL188762   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19969465


    Sources:
    DTC

  • IMGATUZUMAB   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Notes
    Approval Status Preclinical
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    23209031


    Sources:
    TALC MyCancerGenome JAX-CKB

  • GRACILIN J   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19601607


    Sources:
    DTC

  • SAPITINIB   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Response Type sensitive
    combination therapy Sapitinib + Paclitaxel
    Indication/Tumor Type inflammatory breast carcinoma

    PMIDs:
    24886365 20145185


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions

  • CHEMBL1077773   EGFR

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19601607


    Sources:
    DTC

  • LAPATINIB   EGFR

    Interaction Score: 0.63

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Prostate
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture

    PMIDs:
    12214266 16894399 14751502 20110044 20658522 15374980 11752352 14633707 15163842 14737100 14967461 18803986 18408761 25305330 24355130 23917401 18199554 20215545 27595477 22885469 11255078 23022519 22594511 19339720 18784101 18681783 18316547 18003960 16467544 16377102 16257339 14990633 14990632 12648464


    Sources:
    TALC DTC TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TEND DoCM CIViC CancerCommons PharmGKB TTD OncoKB

  • VARLITINIB   EGFR

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name ARRY-334543
    Novel drug target Established target
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • TAK-285   EGFR

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Response Type sensitive
    Indication/Tumor Type squamous cell carcinoma
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    23983820


    Sources:
    JAX-CKB ChemblInteractions

  • MP-412   EGFR

    Interaction Score: 0.49

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    17888033


    Sources:
    TdgClinicalTrial JAX-CKB ChemblInteractions

  • AVELUMAB   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31086949


    Sources:
    CIViC

  • ERLOTINIB HYDROCHLORIDE   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CETUXIMAB SAROTALOCAN   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SIMOTINIB   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THELIATINIB   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CHEMBL2347958   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Lung, Prostate

    PMIDs:
    None found


    Sources:
    CancerCommons

  • SAVOLITINIB   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD9291 + Savolitinib
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive

    PMIDs:
    27694386


    Sources:
    JAX-CKB

  • NAQUOTINIB   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    None found


    Sources:
    JAX-CKB TTD

  • DULIGOTUZUMAB   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome TTD

  • ALLITINIB   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • FUTUXIMAB   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • RG-7160   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Epidermal growth factor receptor erbB1 antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MAB-425   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • JNJ-61186372   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical - Pdx

    PMIDs:
    27216193


    Sources:
    JAX-CKB

  • AZD-4769   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BMS-690514   EGFR

    Interaction Score: 0.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Phase II

    PMIDs:
    23490650


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions TTD

  • TESEVATINIB   EGFR

    Interaction Score: 0.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    22722787


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

  • CANERTINIB   EGFR

    Interaction Score: 0.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    23930994 18408761


    Sources:
    DTC MyCancerGenome CIViC TTD

  • CHEMBL3397300   EGFR

    Interaction Score: 0.31

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Approval Status Phase I
    Response Type sensitive

    PMIDs:
    27836716 27780853


    Sources:
    TALC JAX-CKB MyCancerGenomeClinicalTrial

  • PHA-665752   EGFR

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy PHA-665752 + Sonidegib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    23542356 24165158 26124204


    Sources:
    JAX-CKB

  • POZIOTINIB   EGFR

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    None found


    Sources:
    JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial OncoKB

  • PACRITINIB   EGFR

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    32226941


    Sources:
    CIViC

  • CHEMBL1358137   EGFR

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22944332


    Sources:
    DTC

  • GOLVATINIB   EGFR

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gefitinib + Golvatinib
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive

    PMIDs:
    22789825


    Sources:
    JAX-CKB

  • FALNIDAMOL   EGFR

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • AEE-788   EGFR

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    19147750


    Sources:
    MyCancerGenome JAX-CKB ChemblInteractions

  • CHEMBL1765740   EGFR

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy GSK2334470 + Osimertinib
    Indication/Tumor Type lung cancer
    Response Type sensitive

    PMIDs:
    28416483


    Sources:
    JAX-CKB

  • DURVALUMAB   EGFR

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response
    Approval Status Clinical Study

    PMIDs:
    27225694 31086949


    Sources:
    JAX-CKB CIViC

  • TEGAFUR   EGFR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22486600


    Sources:
    PharmGKB

  • METHYLCURCUMIN   EGFR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25753330


    Sources:
    DTC

  • MDX-447   EGFR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 other
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ALOE-EMODIN   EGFR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16275083


    Sources:
    DTC

  • LAPATINIB DITOSYLATE   EGFR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LY-3164530   EGFR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PYROTINIB   EGFR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DIMETHYLCURCUMIN   EGFR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25753330


    Sources:
    DTC

  • CAPMATINIB   EGFR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type collecting duct carcinoma
    Approval Status Preclinical - Pdx
    combination therapy INC280 + Trametinib

    PMIDs:
    28783719


    Sources:
    JAX-CKB

  • NIVOLUMAB   EGFR

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response
    Approval Status Clinical Study

    PMIDs:
    27225694 28407039 31086949


    Sources:
    JAX-CKB CIViC PharmGKB FDA

  • VANDETANIB   EGFR

    Interaction Score: 0.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Zactima
    Novel drug target Established target
    combination therapy Vandetanib + Temozolomide

    PMIDs:
    25910950 11255078 23022519 22594511 19339720 18784101 18681783 18316547 18003960 16467544 16377102 16257339 14990633 14990632 12648464


    Sources:
    TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial PharmGKB TTD

  • ATEZOLIZUMAB   EGFR

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response
    Approval Status Clinical Study

    PMIDs:
    27225694 31086949


    Sources:
    JAX-CKB CIViC PharmGKB FDA

  • CUDC-101   EGFR

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    20388807


    Sources:
    TALC TdgClinicalTrial JAX-CKB ChemblInteractions TTD

  • SONIDEGIB   EGFR

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gefitinib + Sonidegib
    Response Type no benefit
    Evidence Type Actionable

    PMIDs:
    26124204


    Sources:
    JAX-CKB

  • YUANHUADINE   EGFR

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21916433


    Sources:
    DTC

  • LIFIRAFENIB   EGFR

    Interaction Score: 0.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type lung carcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26208524


    Sources:
    JAX-CKB

  • TYRPHOSTIN AG-1478   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21718029


    Sources:
    DTC

  • CHEMBL219557   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • AFATINIB DIMALEATE   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CRIZOTINIB   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy CO1686 + Crizotinib
    Indication/Tumor Type non-small cell lung carcinoma
    Indication/Tumor Type lung adenocarcinoma

    PMIDs:
    27393507 27283993 27595477 21791641


    Sources:
    JAX-CKB CIViC

  • BOSUTINIB   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Osimertinib + Bosutinib + PF-573328
    Indication/Tumor Type lung cancer
    Response Type sensitive

    PMIDs:
    28416483


    Sources:
    JAX-CKB

  • CEP-32496   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CANERTINIB DIHYDROCHLORIDE   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ERDAFITINIB   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung cancer
    Response Type resistant
    Approval Status Preclinical - Cell culture

    PMIDs:
    28341788


    Sources:
    JAX-CKB

  • PF-00477736   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy PF3644022 + PF-477736
    Indication/Tumor Type Advanced Solid Tumor
    Response Type no benefit

    PMIDs:
    26140595


    Sources:
    JAX-CKB

  • RAMUCIRUMAB   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • LINSITINIB   EGFR

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gefitinib + Linsitinib
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    26561558


    Sources:
    JAX-CKB

  • PEMBROLIZUMAB   EGFR

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response
    Approval Status Clinical Study

    PMIDs:
    27225694 31086949


    Sources:
    JAX-CKB CIViC PharmGKB FDA

  • ENCORAFENIB   EGFR

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Encorafenib
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    27312529


    Sources:
    JAX-CKB

  • OSIMERTINIB MESYLATE   EGFR

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Epidermal growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CHEMBL29197   EGFR

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20095624


    Sources:
    DTC

  • JNJ-26483327   EGFR

    Interaction Score: 0.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • GANETESPIB   EGFR

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Afatinib + Ganetespib
    combination therapy Erlotinib + Ganetespib
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    25077897


    Sources:
    JAX-CKB

  • PIMASERTIB   EGFR

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pimasertib + BEZ235
    Approval Status Preclinical - Cell line xenograft
    combination therapy Pimasertib + Sorafenib

    PMIDs:
    23629727


    Sources:
    JAX-CKB

  • PEMETREXED   EGFR

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24636847 31605797


    Sources:
    CIViC

  • CABOZANTINIB   EGFR

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type unknown

    PMIDs:
    27694386 27825638


    Sources:
    JAX-CKB

  • ROGARATINIB   EGFR

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TALAZOPARIB   EGFR

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31852834


    Sources:
    CIViC

  • CEP-11981   EGFR

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22148921


    Sources:
    DTC

  • DECITABINE   EGFR

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    24874286


    Sources:
    JAX-CKB

  • SELUMETINIB   EGFR

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Osimertinib + Selumetinib
    Indication/Tumor Type lung adenocarcinoma
    Approval Status Preclinical

    PMIDs:
    24939055 28416483 25870145 27287717 27312529


    Sources:
    JAX-CKB

  • SARACATINIB   EGFR

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    28416483


    Sources:
    JAX-CKB

  • AMLEXANOX   EGFR

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Amlexanox + Selumetinib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    27287717


    Sources:
    JAX-CKB

  • TEMOZOLOMIDE   EGFR

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy ABT-414 + Temozolomide + Radiotherapy
    Indication/Tumor Type glioblastoma multiforme
    Response Type predicted – sensitive

    PMIDs:
    25910950 26846818


    Sources:
    JAX-CKB

  • BMS-754807   EGFR

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BMS-754807 + Dacomitinib
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    26561558


    Sources:
    JAX-CKB

  • PLUMBAGIN   EGFR

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24355130


    Sources:
    DTC

  • IBRUTINIB   EGFR

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    24915291


    Sources:
    DTC

  • GELDANAMYCIN   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18652519


    Sources:
    PharmGKB

  • CARBOPLATIN   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22581822 22370314 22285168 21900837 21783417 20573926 20022809 19692680 22139083


    Sources:
    CIViC PharmGKB

  • GEDATOLISIB   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gedatolisib + Neratinib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    21325073 19238632 16731747


    Sources:
    JAX-CKB

  • PACLITAXEL   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Sapitinib + Paclitaxel
    Indication/Tumor Type inflammatory breast carcinoma
    Response Type sensitive

    PMIDs:
    24886365 22581822 22370314 22285168 21900837 21783417 20573926 20022809 19692680 22139083


    Sources:
    JAX-CKB CIViC PharmGKB

  • TEMSIROLIMUS   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type no benefit
    combination therapy Temsirolimus + Erlotinib
    Indication/Tumor Type malignant glioma

    PMIDs:
    24470557


    Sources:
    JAX-CKB

  • LIDOCAINE   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name PSD502, lidocaine + prilocaine
    Novel drug target Established target

    PMIDs:
    16551906


    Sources:
    TdgClinicalTrial

  • GLESATINIB   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MGCD265 + Erlotinib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • SIROLIMUS   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Afatinib + Cetuximab + Sirolimus
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive

    PMIDs:
    24934779 24813888 18089823 25157968


    Sources:
    JAX-CKB DoCM CIViC

  • TRAMETINIB   EGFR

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell line xenograft
    Indication/Tumor Type collecting duct carcinoma
    Approval Status Preclinical - Pdx

    PMIDs:
    28783719 27312529 26582713 26036643


    Sources:
    JAX-CKB

  • MK-2206   EGFR

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Erlotinib + MK2206
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    26106072


    Sources:
    JAX-CKB

  • REGORAFENIB   EGFR

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pimasertib + Regorafenib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    23629727


    Sources:
    JAX-CKB PharmGKB

  • DABRAFENIB   EGFR

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trametinib + Dabrafenib
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    27312529


    Sources:
    JAX-CKB

  • NITROGLYCERIN   EGFR

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TRASTUZUMAB   EGFR

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11752352


    Sources:
    TEND

  • PONATINIB   EGFR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    22238366


    Sources:
    JAX-CKB

  • PUQUITINIB   EGFR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SORAFENIB   EGFR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pimasertib + Sorafenib
    Approval Status Preclinical - Cell line xenograft
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    23629727 26743856 24166906 26318998


    Sources:
    DTC JAX-CKB TTD

  • BUPARLISIB   EGFR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BKM120 + Osimertinib
    Indication/Tumor Type lung cancer
    Response Type sensitive

    PMIDs:
    28416483


    Sources:
    JAX-CKB

  • VATALANIB   EGFR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • LEUCOVORIN   EGFR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22486600


    Sources:
    PharmGKB

  • VEMURAFENIB   EGFR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Vemurafenib + Gefitinib
    combination therapy Vemurafenib + Panitumumab
    Response Type sensitive

    PMIDs:
    27312529


    Sources:
    JAX-CKB

  • DACTOLISIB   EGFR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pimasertib + BEZ235
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    24939055 23629727


    Sources:
    JAX-CKB

  • BEVACIZUMAB   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Erlotinib
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive

    PMIDs:
    28408243


    Sources:
    JAX-CKB

  • IMATINIB   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    22323597 28762371


    Sources:
    JAX-CKB PharmGKB

  • RIBAVIRIN   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28703131


    Sources:
    PharmGKB

  • SB-202190   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22951114


    Sources:
    DTC

  • IRINOTECAN   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Irinotecan + Nimotuzumab
    Indication/Tumor Type stomach cancer
    Response Type predicted – sensitive

    PMIDs:
    25185971 23209031


    Sources:
    JAX-CKB

  • SUNITINIB   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Sunitinib
    Indication/Tumor Type olfactory neuroblastoma
    Response Type sensitive

    PMIDs:
    27149458


    Sources:
    JAX-CKB

  • EVEROLIMUS   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Everolimus + Pimasertib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    23629727


    Sources:
    JAX-CKB

  • DORAMAPIMOD   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZD-1152-HQPA   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAK-715   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ETOPOSIDE   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type neuroblastoma
    Response Type resistant
    Approval Status Preclinical - Cell culture

    PMIDs:
    27216155


    Sources:
    JAX-CKB

  • DOCETAXEL   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22285168 21783417


    Sources:
    PharmGKB

  • GEMCITABINE   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22285168 21783417


    Sources:
    PharmGKB

  • MLN-8054   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • STAUROSPORINE   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DASATINIB   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dasatinib + Osimertinib
    Indication/Tumor Type lung cancer
    Response Type sensitive

    PMIDs:
    28416483


    Sources:
    JAX-CKB

  • CURCUMIN   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25753330


    Sources:
    DTC

  • CISPLATIN   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy ER2 + Cisplatin
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    23764753 27040853


    Sources:
    JAX-CKB CIViC

  • GW843682X   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ALISERTIB   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • GO-6976   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ALCOHOL   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10092515


    Sources:
    NCI

  • PD-0166285   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • FLUOROURACIL   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23816762


    Sources:
    PharmGKB

  • SOTRASTAURIN   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TOZASERTIB   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • R-406   EGFR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RG-1530   EGFR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CYC-116   EGFR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAE-684   EGFR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ILORASERTIB   EGFR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CENISERTIB   EGFR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Ensembl: ENSG00000146648

    • Version: 101_38

    Alternate Names:
    EGFR Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P00533

    • Version: January-2014

    Alternate Names:
    EGFR Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass EC:2.7.10.1

    Publications:

  • CancerCommons: EGFR

    • Version: 25-July-2013

    Alternate Names:
    1956 Entrez Gene ID

    Gene Info:
    CancerCommons Reported Gene Name EGFR

    Publications:

  • TEND: P00533

    • Version: 01-August-2011

    Alternate Names:
    EGFR_HUMAN Uniprot Id
    ENSG00000146648 Ensembl Gene Id
    P00533 Uniprot Accession

    Gene Info:
    Target Subclass Kinase
    Target Main Class Receptors
    Transmembrane Helix Count 1

    Publications:

  • RussLampel: ENSG00000146648

    • Version: 26-July-2011

    Alternate Names:
    EGFR Display Id
    ENSG00000146648 Ensembl Gene Id
    EPIDERMAL GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P00533] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • BaderLabGenes: EGFR

    • Version: February-2014

    Alternate Names:
    1956 Entrez Gene ID

    Gene Info:
    Initial Gene Query EGFR
    Counted Citations from 1950-2000 12181

    Gene Categories:
    KINASE

    Publications:

  • HopkinsGroom: P00533

    • Version: 11-September-2012

    Alternate Names:
    P00533 Uniprot Accession
    1956 Entrez Gene Id
    EGFR Uniprot Gene Name

    Gene Info:
    Interpro Type Domain
    Interpro Acc IPR001245
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • JAX-CKB: EGFR

    • Version: 27-September-2017

    Alternate Names:
    1956 CKB Entrez Id
    EGFR CKB Gene Synonym
    ERBB CKB Gene Synonym

    Gene Info:

    Publications:
    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
    Gainor et al., 2016, EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis., Clin. Cancer Res.
    Suzuki et al., 2007, Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor., Cancer Sci.

  • PharmGKB: EGFR

    • Version: 18-August-2020

    Alternate Names:
    PA7360 PharmGKB ID

    Gene Info:

    Publications:
    Funke S et al., 2008, Pharmacogenetics in colorectal cancer: a systematic review., Pharmacogenomics
    Liu G et al., 2008, Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib., Pharmacogenomics J
    Han et al., 2012, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung., J. Clin. Oncol.

  • CIViC: EGFR

    • Version: 14-September-2020

    Alternate Names:
    1956 Entrez Gene ID
    19 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE, CLINICALLY ACTIONABLE

    Publications:
    Yun et al., 2008, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP., Proc. Natl. Acad. Sci. U.S.A.
    Kancha et al., 2009, Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy., Clin. Cancer Res.
    Walter et al., 2013, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC., Cancer Discov

  • TTD: Epidermal growth factor receptor

    • Version: 2020.06.01

    Alternate Names:
    EGFR TTD Gene Abbreviation
    T59328 TTD Target ID

    Gene Info:

    Publications:
    Klinguer-Hamour C et al., 2014, World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA., MAbs
    Newman DJ et al., 2014, Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development., Mar Drugs

  • NCI: EGFR

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Zhang et al., 1999, Chronic ethanol consumption disrupts complexation between EGF receptor and phospholipase C-gamma1: relevance to impaired hepatocyte proliferation., Biochem. Biophys. Res. Commun.

  • DoCM: EGFR

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
    Rajasekaran et al., 2010, In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs., Appl. Biochem. Biotechnol.
    Miller et al., 2012, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial., Lancet Oncol.

  • DTC: EGFR

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Rateb ME et al., 2009, Bioactive diterpene derivatives from the marine sponge Spongionella sp., J Nat Prod
    Ban HS et al., 2010, Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines., Bioorg Med Chem
    Blair JA et al., 2007, Structure-guided development of affinity probes for tyrosine kinases using chemical genetics., Nat Chem Biol

  • TALC: HER1

    • Version: 12-May-2016

    Alternate Names:
    HER1 Gene Symbol

    Gene Info:

    Publications:

  • TALC: EGFR

    • Version: 12-May-2016

    Alternate Names:
    EGFR Gene Symbol

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000146648

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000146648 Gene Symbol
    EGFR Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • MyCancerGenome: EGFR

    • Version: 20-Jun-2017

    Alternate Names:
    1956 Entrez Gene Id
    EGFR MyCancerGenome Gene Symbol
    EGFR (HER1/ERBB1) MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • ChemblInteractions: ERBB

    • Version: chembl_23

    Alternate Names:
    ERBB1 GENE_SYMBOL
    HER1 GENE_SYMBOL
    EGFR GENE_SYMBOL

    Gene Info:

    Publications:

  • OncoKB: EGFR

    • Version: 23-July-2020

    Alternate Names:
    ERBB1 OncoKB Gene Synonym
    1956 OncoKB Entrez Id
    PIG61 OncoKB Gene Synonym

    Gene Info:

    Publications:

  • GO: EGFR

    • Version: 01-February-2022

    Alternate Names:
    ERBB GO Gene Synonym
    ERBB1 GO Gene Synonym
    HER1 GO Gene Synonym

    Gene Info:

    Gene Categories:
    CELL SURFACE, TYROSINE KINASE

    Publications:

  • Tempus: EGFR

    • Version: 11-November-2018

    Alternate Names:
    EGFR Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: EGFR

    • Version: 27-Jun-2013

    Alternate Names:
    1956 Gene ID
    ERBB dGene Synonym
    ERBB1 dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, TYROSINE KINASE

    Publications:

  • Pharos: EGFR

    • Version: 01-February-2022

    Alternate Names:
    Epidermal growth factor receptor Gene Name
    P00533 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • ClearityFoundationBiomarkers: EGFR

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • MyCancerGenomeClinicalTrial: EGFR

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationClinicalTrial: EGFR

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • MskImpact: EGFR

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FoundationOneGenes: EGFR

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: EGFR

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FDA: EGFR

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

  • Oncomine: EGFR

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • COSMIC: EGFR

    • Version: 4-Sep-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21